Kalaris Therapeutics

(NASDAQ) KLRS

Current Price$4.73

Market Cap$107.78M

Since IPO (2025)-61%

5 Year-99%

1 Year+86%

1 Month+2%

Kalaris Therapeutics Financials at a Glance

Market Cap

$107.78M

Revenue (TTM)

$0.00

Net Income (TTM)

-$44.10M

EPS (TTM)

-$2.14

P/E Ratio

-2.12

Dividend

$0.00

Beta (Volatility)

1.31 (Average)

Dividend

$0.00

Beta (Volatility)

1.31 (Average)

Price

$4.73

Volume

56,292.436

Open

$4.55

Price

$4.73

Volume

56,292.436

Open

$4.55

Previous Close

$4.75

Daily Range

$4.38 - $4.80

52-Week Range

$2.14 - $11.88

Estimated Earnings Date

Aug 12, 2026

Dividend

$0.00

Beta (Volatility)

1.31 (Average)

Price

$4.73

Volume

56,292.436

Open

$4.55

Previous Close

$4.75

Daily Range

$4.38 - $4.80

52-Week Range

$2.14 - $11.88

Estimated Earnings Date

Aug 12, 2026

KLRS News

Kalaris Reports Loss Cash at 88 Million

Motley Fool Markets TeamAug 13, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kalaris Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Andrew Oxtoby, MBA

Website

www.kalaristx.com

Headquarters

Cambridge, MA 02142, US

KLRS Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-72.78%

Return on Capital

-57.50%

Return on Assets

-40.16%

Earnings Yield

-47.17%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$107.78M

Shares Outstanding

23.79M

Volume

56.29K

Avg. Volume

89.08K

Financials (TTM)

Gross Profit

-$20.00K

Operating Income

-$47.63M

EBITDA

-$44.08M

Operating Cash Flow

-$48.89M

Capital Expenditure

-$200.00K

Free Cash Flow

-$49.09M

Cash & ST Invst.

$97.22M

Total Debt

$1.41M

Kalaris Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$10.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$107.78M

N/A

Market Cap/Employee

$7.70M

N/A

Employees

N/A

Net Income

-$10.86M

-6.5%

EBITDA

-$10.85M

-23.9%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$97.22M

-3.7%

Total Debt

$1.41M

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$1.09M

N/A

Short Term Debt

$317.00K

N/A

Return on Assets

-40.16%

N/A

Return on Invested Capital

-46.82%

N/A

Free Cash Flow

-$13.35M

-79.4%

Operating Cash Flow

-$13.35M

-79.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IMAImageneBio Inc

IMAImageneBio Inc$5.83+1.04%

CNTBConnect Biopharma Holdings Limited

CNTBConnect Biopharma Holdings Limited$2.46+2.93%

CNTXContext Therapeutics Inc.

CNTXContext Therapeutics Inc.$0.65+7.46%

IFRXInflaRx N.V.

IFRXInflaRx N.V.$2.24-3.86%

MGXMetagenomi, Inc. Common Stock

MGXMetagenomi, Inc. Common Stock$1.26+4.13%

QNCXQuince Therapeutics, Inc.

QNCXQuince Therapeutics, Inc.$17.23+2.87%

ARTVArtiva Biotherapeutics, Inc.

ARTVArtiva Biotherapeutics, Inc.$9.61-1.94%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$17.92-0.01%

TAT&T

TAT&T$20.58+0.00%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$12.30-0.15%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$73.35-0.05%

ONDSOndas

ONDSOndas$7.41-0.06%

CLROClearOne

CLROClearOne$6.48+1.01%

SOFISoFi Technologies

SOFISoFi Technologies$18.24-0.01%

Questions About KLRS

What is the current price of Kalaris Therapeutics?

Kalaris Therapeutics is trading at $4.75 per share.

What is the 52-week range for Kalaris Therapeutics?

Over the past 52 weeks, Kalaris Therapeutics has traded between $2.14 and $11.88.

How much debt does Kalaris Therapeutics have?

As of the most recent reporting period, Kalaris Therapeutics reported total debt of $1.41M.

How much cash does Kalaris Therapeutics have on hand?

Kalaris Therapeutics reported $34.43M in cash and cash equivalents in its most recent financial results.

What is Kalaris Therapeutics’s dividend yield?

Kalaris Therapeutics does not currently have a dividend yield.

Kalaris Therapeutics

Kalaris Therapeutics Financials at a Glance

KLRS News

Kalaris Reports Loss Cash at 88 Million

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Kalaris Therapeutics

KLRS Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Kalaris Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About KLRS

What is the current price of Kalaris Therapeutics?

What is the 52-week range for Kalaris Therapeutics?

How much debt does Kalaris Therapeutics have?

How much cash does Kalaris Therapeutics have on hand?

What is Kalaris Therapeutics’s dividend yield?

Premium Investing Services